Minneapolis, MN – Nationally ranked startup accelerator gener8tor will host its inaugural gBETA Medtech LiveBETA (“Demo Day”) event on May 21st at the McNamara Alumni Center. The gBETA Medtech accelerator launched in March thanks to the sponsorship of Boston Scientific, with additional support from Mayo Clinic, the University of Minnesota, and the Medical Alley Association. gBETA Medtech is a free, seven-week accelerator that works with medical device, healthcare-related software, biotech and diagnostics startups. Each program is capped at five to six teams, and requires no fees and no equity. Participants receive intensive and individualized coaching and access to physicians, researchers, successful entrepreneurs, angel investors, venture capitalists and industry experts. The program is designed to help startups gain early customer traction on their product or idea, and establish metrics that make them competitive applicants for full-time, equity-based accelerators or seed investment.
gBETA Medtech “Spring 2018” kicked off March 22nd with six local Medtech startups selected from an all-Minnesota applicant pool of 30 companies. Descriptions for all six companies can be found at the bottom of this release.
The cohort graduates on May 21 during LiveBETA (“Demo Day”) where the six companies will deliver five-minute pitches to an audience of investors, entrepreneurs, mentors, and community members. The event will feature opening remarks from Jeff Mirviss, senior vice president and president, Peripheral Interventions Division at Boston Scientific and Vice Chair of the Medical Alley Association . The Medical Alley Association will also be hosting a panel discussion on “The State of Medtech Innovation in Minnesota.”
There will be an opportunity before and after the presentations to mingle with the startup companies and other attendees. LiveBETA is a free event, but those interested in attending are asked to RSVP.
gBETA Medtech runs three times per year with five to six companies per cohort to ensure a high level of individualized attention. gBETA Medtech works exclusively with startups focused on healthcare, including: healthcare products for diagnosing, treating and/or monitoring diseases or medical conditions including devices, software, biological technology, and healthcare services, as well as technology or process innovations that could serve any component of the supply chain.
gBETA Medtech is now accepting applications for the second 2018 cohort. Applications are open to startups across the globe. Startups interested in applying should contact gBETA Medtech Director Adam Choe (email@example.com). For more information on the program and ways to get involved, please visit www.gbetamedtech.com.
gBETA Medtech Spring 2018 Cohort
ExpressionMed creates supplemental medical adhesives that increase the longevity and comfort of wearable medical devices while adding an element of customization through design. ExpressionMed has helped families in 49 states and 20 different countries and has seen an average of 54% month-over-month revenue growth since June of 2017 totaling $64,152. CEO: Meghan Sharkus | firstname.lastname@example.org | www.expressionmed.com
Kobara Medical designs and manufactures cardiac rhythm management (CRM) and neuromodulation devices. Kobara’s cardiac lead technology provides electrophysiologists and surgeons a single solution to treat heart failure and cardiac arrhythmias. Kobara Medical has raised $120K, acquired pre-clinical and clinical data to demonstrate feasibility and clinical impact, and has built its first Cobra Pacing Lead that will be tested in a subchronic animal study in Q2 of 2018. CEO: Andreas Pfahnl, Sc.D. | email@example.com | www.kobara-medical.com
NeuroVASx designs and manufactures alternative solutions for embolizing vessel abnormalities. NeuroVASx provides clinical benefits by reducing the incidence of compaction and migration, reducing the need for retreatment. NeuroVASx owns an intellectual property portfolio of 13 patents within the focus area of endovascular delivery systems, implants, and manufacturing processes. CEO: Steve Ferry | firstname.lastname@example.org
Quench Medical develops novel formulations of approved inhaler medications to significantly decrease symptoms of lung diseases. Quench Medical’s first indication is severe asthma, where patients suffer costly exacerbations from uncontrolled symptoms. Quench Medical received a $225K SBIR grant from the National Institutes of Health in March 2018. CEO: Bryce Beverlin II Ph.D. | email@example.com | www.quenchmedical.net
Soundly reduces snoring by guiding the user through a gamified therapy to strengthen and tone their upper airway. Soundly reduces snoring without needing bulky devices during sleep. Soundly has received $80,000 in non-dilutive funding from the NSF and NIH and recently completed a beta test of 600 users where 90% of surveyed users reported reductions in snoring. CEO: Brian Krohn Ph.D. | firstname.lastname@example.org | www.sleepsound.ly
Vitrose Health provides an efficient way to diagnose common illnesses through a direct-to-consumer testing solution. Vitrose Health creates a new alternative for non-urgent care that is more efficient and affordable for both the patient and the healthcare system. Vitrose Health was established in November of 2017 and is part of the Spring 2018 gBETA Medtech accelerator. CEO: Bharat Pulgam | email@example.com | www.vitrosehealth.com
gBETA is a program of nationally ranked startup accelerator gener8tor. gBETA Medtech is a free, seven-week accelerator that works with medical device, healthcare-related software, biotech and diagnostics startups. Each program is capped at five to six teams, and requires no fees and no equity. Participants receive intensive and individualized coaching and access to physicians, researchers, successful entrepreneurs, angel investors, venture capitalists and industry experts. The program is designed to help startups gain early customer traction on their product or idea, and establish metrics that make them competitive for full-time, equity-based accelerators or seed investment.
gener8tor is a nationally ranked accelerator that invests in high-growth startups. Three times a year gener8tor invests $90K in each of five startups who receive a concierge experience during its 12-week accelerator program. gener8tor supports the growth of these startups through its network of experienced mentors, technologists, corporate partners, angel investors and venture capitalists.
To date, gener8tor’s 65 alumni have cumulatively raised more than $150M in follow-on financing. Of these 65 alumni, 58% have raised more than $1M in follow-on financing or have been acquired.
gener8tor invests in high-growth startups, including software, IT, web, SaaS, life science, medtech, e-commerce and hardware. Accepted startups receive $90K and 12 weeks of mentorship-driven programming. gener8tor is a proud member of the Global Accelerator Network (GAN) and is sponsored by American Family Insurance . gener8tor is a GOLD-tier accelerator in the U.S. as ranked by the Seed Accelerator Rankings Project .